Cullinan Therapeutics financials
$15.23+1.87%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$57.3M | -$53.7M | -$55.3M | -$55.6M | -$75.8M | -$55.0M | -$55.0M | -$48.9M | -$50.0M | -$43.0M | -$45.5M | -$45.2M |
| Net income | -$53.7M | -$45.5M | -$29.0M | -$50.6M | -$70.1M | -$43.7M | -$29.7M | -$40.6M | -$42.0M | -$32.3M | -$4.1M | -$39.2M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.87 | $-0.75 | $-0.49 | $-0.86 | $-1.19 | $-0.74 | $-0.51 | $-0.69 | $-0.75 | $-0.75 | $-0.10 | $-0.91 |
| EBITDA | -$57.2M | -$53.6M | -$55.2M | -$55.5M | -$75.7M | -$54.9M | -$55.0M | -$48.8M | -$50.0M | -$42.9M | -$45.4M | -$44.7M |
| Operating cash flow | -$38.2M | -$46.0M | -$38.1M | -$36.9M | -$57.6M | -$43.2M | -$36.6M | -$34.1M | -$36.3M | -$38.2M | -$18.1M | -$34.1M |
| Free cash flow | -$38.2M | -$46.0M | -$38.1M | -$36.9M | -$57.6M | -$43.2M | -$36.6M | -$34.1M | -$36.3M | -$38.2M | -$18.1M | -$34.1M |
| Diluted shares | 61.5M | 60.5M | 59.2M | 59.1M | 59.0M | 58.9M | 58.7M | 58.3M | 55.1M | 43.0M | 42.8M | 42.7M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $78.6M | $75.1M | $88.3M | $103.3M | $72.8M | $76.7M |
| Short-term investments | $255.9M | $276.8M | $289.6M | $229.3M | $192.7M | $227.2M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $363.8M | $403.0M | $448.4M | $484.1M | $520.3M | $579.7M |
| Total liabilities | $42.0M | $36.8M | $39.6M | $32.8M | $28.2M | $27.8M |
| Shareholders' equity | $321.8M | $366.2M | $408.7M | $451.4M | $492.1M | $551.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology